Summary of clinical-pathological characteristics of studies reporting associations between +p53-AAbs and survival in ovarian cancer.

↓: diminished↑: increased; p53-AAbs: p53 autoantibodies; y: years; m: months; FIGO: International Federation of Gynecology and Obstetrics; NOS: Newcastle-Ottawa Quality Assessment Scale; perc.: percentile; Uni: univariate; Multi: multivariate; NA: Not Available; TRI: Time-resolved immunofluorimetric assay; S: Serous; U: Undifferentiated; M: Mucinous; C: Clear cell; E: Endometroid; Mx: Mixed; P: Papillary; O: Other; G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated; G4: undifferentiated;Rx: Residual tumour size indefinite1NOS score (range, 1–9) was assigned only to the included studies253/130 patients enrolled prior to first surgery3all these patients (N = 43) had III-IV FIGO stage446/99 patients enrolled prior to first surgery5Follow-up data available for patients dead and alive6data available only for patients with serous tumour histotype.Summary of clinical-pathological characteristics of studies reporting associations between +p53-AAbs and survival in ovarian cancer.